Kraus explains current unmet needs in IgA nephropathy and what sibeprenlimab may offer based on the phase 3 VISIONARY study.
John Kraus, MD, PhD
Advertisement
John Kraus, MD, PhD, is the executive vice president and chief medical officer of Otsuka Pharmaceuticals.
Articles by John Kraus, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Interstitial Lung Abnormalities: Recognition, Risk Stratification, and When to Act
2
Q&A: Intensive LDL Lowering and Cardiovascular Prevention Strategies, With Lawrence Leiter, MD
3
Management Strategies for Hypercortisolism
4
Evaluating Clinical and Real-World Evidence in Hypercortisolism
5